NORD and 98 organizations send letter to Congressional leadership to resume negotiations to develop a comprehensive FDA user fee package
Published: Aug 1, 2022
Tagged in: User Fee Act
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD and 98 organizations send letter to Congressional leadership to resume negotiations to develop a comprehensive FDA user fee package
Published: Aug 1, 2022
Tagged in: User Fee Act
NORD and 70 other organizations urge Senate HELP and House Energy and Commerce leadership to address clinical trial diversity in the PDUFA reauthorization
Published: Jul 11, 2022
Tagged in: User Fee Act, Clinical Trials
NORD and 71 organizations urge Senate HELP committee to incorporate Title V in the House PDUFA bill
Published: Jun 8, 2022
Tagged in: User Fee Act, Clinical Trials
NORD and 88 patient organizations send letter to Congressional leaders urging them to improve clinical trial diversity as part of PDUFA reauthorization
Published: May 11, 2022
Tagged in: User Fee Act
NORD submits a statement for the record on H.R. 7667, the Food and Drug Amendments of 2022.
Published: May 11, 2022
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
NORD submits a statement for the record to the Senate Committee on Health, Education, Labor and Pension regarding the FDA’s user fee agreements
Published: Apr 5, 2022
Tagged in: User Fee Act, FDA’s Accelerated Approval Pathway, Advancing Rare Disease Research and Regulatory Science
